Results of JUPITER-02, a Phase 3 clinical trial evaluating the investigational new drug, Toripalimab, plus chemotherapy for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), were selected for presentation during the American Society of Clinical Oncology’s (ASCO’s)
In addition to the JUPITER-02 late-breaking abstract, ASCO accepted for publication or presentation more than two dozen additional abstracts, primarily investigator-sponsored studies, that evaluate the utility of toripalimab in a variety of cancer types including lung cancer, melanoma, urothelial carcinoma, gastroesophageal cancer, and
Listen to the virtual event reviewing the clinical data presented at ASCO and providing an overview of the toripalimab clinical development program.Access the event
McDavid Stilwell, [email protected]
Sheryl Seapy, [email protected]
U.S. Healthcare professionals:
Submit inquiry here.